sc 58125 has been researched along with Anoxemia in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abbate, A; Al-Husseini, A; Chalfant, CE; Drake, JI; Farkas, L; Kraskauskas, D; Van Tassel, B; Voelkel, NF; Wijesinghe, DS | 1 |
| Brunette, E; Gendron, TF; Mealing, GA; Morley, P; Nguyen, A; Tauskela, JS | 1 |
2 other study(ies) available for sc 58125 and Anoxemia
| Article | Year |
|---|---|
Increased eicosanoid levels in the Sugen/chronic hypoxia model of severe pulmonary hypertension.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Arachidonate 5-Lipoxygenase; Arterioles; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Diethylcarbamazine; Dinoprost; Dinoprostone; Humans; Hypertension, Pulmonary; Hypoxia; Inflammation; Leukotriene D4; Lipoxygenase Inhibitors; Lung; Male; Prostaglandins F; Pulmonary Artery; Pyrazoles; Rats; Rats, Sprague-Dawley; Thromboxane B2; Ventricular Function, Right | 2015 |
Opposing effects of cyclooxygenase-2 selective inhibitors on oxygen-glucose deprivation-induced neurotoxicity.
Topics: Animals; Calcium; Canada; Cell Death; Cells, Cultured; Cerebral Cortex; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Cytosol; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration Schedule; Enzyme Induction; Extracellular Space; Glucose Metabolism Disorders; Glutamates; Hypoxia; Mice; Mice, Inbred C57BL; Neurotoxicity Syndromes; Nitrobenzenes; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Rats; Rats, Sprague-Dawley; Receptors, N-Methyl-D-Aspartate; Sulfonamides; Time Factors | 2004 |